Egetis Therapeutics: TRIAC II did not meet its primary neurocognitive endpoints - Redeye

Redeye comments on the news that the company’s complementary clinical study TRIAC II, which focused on neurocognition in young MTC8 patients, did not achieve its co-primary endpoints. However, it did replicate findings needed for regulatory approvals. We give our initial comment.

Länk till analysen i sin helhet: https://www.redeye.se/research/1016638/egetis-therapeutics-triac-ii-did-not-meet-its-primary-neurocognitive-endpoints?utm_source=finwire&utm_medium=RSS